Treakisym bendamustine regulatory update

SymBio and Eisai said Japan approved an expanded label for Treakisym bendamustine to include treatment of chronic lymphocytic leukemia (CLL). Eisai markets the alkylating agent in Japan to treat relapsed or refractory low-grade B cell non-Hodgkin’s lymphoma (NHL) and mantle cell lymphoma (MCL). Last December, SymBio submitted a regulatory application in Japan for the product for first-line treatment of NHL and MCL. ...